Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19

Home Page
About
Submit A Journal
Submit A Conference
Submit Paper/Book
- Submit a Preprint
- Submit a Book
Contact

Eurasian Journal of Critical Care
Volume:4 Issue:3
Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19

Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19

Pages : 116-118

View : 21 | Download : 13

Publication Date : 2022-12-30

Article Type : Review Paper

Abstract :The novel coronavirus disease 2019 insert ignore into journalissuearticles values(COVID-19); emerged in China in late December 2019 and quickly spread to many countries around the world. Antiviral drugs are candidate treatments for the treatment of COVID-19. Molnupiravir, the first oral antiviral drug, is a drug with anti-RNA polymerase activity and is currently being used for the treatment of COVID-19 patients. In this review, we aimed to discuss the mechanism of action, safety, efficacy and clinical studies of molnupiravir in the treatment of patients with COVID-19.
Keywords : SARS CoV 2, COVID 19, Molnupiravir

ORIGINAL ARTICLE URL

VIEW PAPER (PDF)

* There may have been changes in the journal, article,conference, book, preprint etc. informations. Therefore, it would be appropriate to follow the information on the official page of the source. The information here is shared for informational purposes. IAD is not responsible for incorrect or missing information.